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Introduction: Indications for surgical resection for small cell lung 
cancer (SCLC) have been very limited. Because early-stage SCLC is 
a rare presentation of lung cancer, studies comparing surgical resec-
tion among a large number of patients are unlikely to be conducted. 
This study reports the most recent surgical outcomes of a large 
number of SCLC patients who underwent surgery in 2004.Methods: 
In 2010, the Japanese Joint Committee of Lung Cancer Registry 
performed a nationwide retrospective registry study regarding the 
prognosis and clinicopathologic profiles of 11,663 patients who 
underwent resection for primary lung cancer in 2004. Of the 11,663 
patients, 243 patients with SCLC (2.1%) were included in this study. 
The registry data of the patients with SCLC were analyzed, and the 
clinicopathologic profiles and surgical outcomes of the patients were 
evaluated.Results: The 5-year survival rate for all cases (n = 243, 213 
males, mean age 68.2 years) was 52.6%. The 5-year survival rates by 
c-stage and p-stage were as follows: IA, 64.3% (n = 132) and 72.3% 
(n = 93); IB, 45.7% (n = 36) and 61.1% (n = 51); IIA, 50.5% (n =25); 
and 44.8% (n = 27); IIB, 33.3% (n = 10) and 40.3% (n = 17); IIIA, 
30.5% (n = 30) and 23.4% (n = 45); and IV, 0% (n = 7) and 0% (n = 
9), respectively. A multivariate analysis showed that the significant 
prognostic factors were age, gender, c-stage, and surgical curability. 
A kappa value was moderate conformity between c-stage and p-stage 
in all cases.Conclusions: Surgical resection in selected patients with 
early-stage SCLC, especially stage I, had favorable results.
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Lung cancer is the leading cause of cancer-related death in the United States and in Japan. Small cell lung cancer 
(SCLC) represents only 13–20% of all lung cancers.1 It is dis-
tinguished by its rapid growth rate and early dissemination 
to regional lymph nodes and distant sites. Therefore, SCLC 
represents less than 5% of cases in large surgical series.2
In 1973, the Medical Research Council3 reported a 
postoperative survival rate that was as poor as the survival 
rate for nonsurgical treatment in SCLC patients. In addition, 
Mountain4 reported that there was no difference in outcome 
between resected and non-resected cases in 368 SCLC patients. 
After those two studies were published, the standard treatment 
for SCLC became chemotherapy and/or radiation, and sur-
gery was basically contraindicated. In 1983, the Lung Cancer 
Study Group5 initiated the only randomized trial of adjuvant 
surgical resection after induction chemotherapy. This trial 
failed to show improved survival rates after surgery compared 
with radiation after neoadjuvant chemotherapy. Thereafter, 
several authors reported rather favorable surgical results in a 
relatively small number of patients with early-stage SCLC.6,7 
Shepherd and colleagues8 reported in 1988 that the postopera-
tive 5-year survival rate was 31% in 77 patients with surgery 
as the primary treatment for SCLC. In 2005, Japan Clinical 
Oncology Group reported a 68% 3-year postoperative survival 
rate in patients with resected clinical stage I SCLC undergo-
ing postoperative adjuvant chemotherapy.9 Recently, several 
large cohort studies of surgery for limited disease SCLC have 
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been reported.10,11 An analysis of 205 clinical stage IA SCLC 
patients from the National Cancer Institute’s Surveillance 
Epidemiology and End Results database who underwent radi-
cal lobectomy showed a 5-year survival rate of 50.3% without 
postoperative adjuvant radiotherapy.12
However, optimal indications for surgical resection for 
SCLC and the efficacy of perioperative chemotherapy have 
not yet been determined. Because early-stage SCLC is a rare 
presentation, accounting for 2.4% to 3.4% of resected lung 
cancer,13 and a definite preoperative diagnosis of cell type as 
SCLC is rather difficult, studies prospectively comparing the 
significance of surgical resection in a large number of cases 
are unlikely to be conducted.
This study aimed to investigate recent surgical results 
for SCLC patients retrospectively, based on the large-volume 
Japanese nationwide registry database.
PATIENTS AND METHODS
Patients
In 2010, the Japanese Joint Committee of Lung Cancer 
Registry performed a nationwide retrospective registry study 
regarding the prognoses and clinicopathologic profiles of 
11,663 patients who underwent resection for primary lung 
cancer in 2004. Of those patients, 243 with histologically con-
firmed SCLC (2.1%) were extracted from the database. The 
clinicopathologic factors and their relationship to postopera-
tive survival were evaluated.
The following items were included for analysis: gender, 
age, smoking status, serum tumor markers (carcinoembryonic 
antigen and proGRP), clinical tumor, node, metastasis (TNM) 
stage (c-stage), pathological TNM stage (p-stage), surgical 
procedure, surgical curability (R0 and R1/R2), presence or 
absence of preoperative and postoperative chemotherapy, and 
survival time. The Union for International Cancer Control 
TNM staging, version 7,14 was adopted in this study.
This study and the Japanese Joint Committee of Lung 
Cancer Registry registration study adhere to the Ethical 
Guidelines for Epidemiologic Research imposed by the 
Japanese Ministry of Health, Labor, and Welfare.15
Statistical Analysis
Survival time was defined as the time from the date of 
the surgery to the date of the last follow-up. Survival curves 
were estimated by the Kaplan-Meier method. Differences in 
survival were assessed by the log-rank test. A multivariate 
analysis by Cox’s proportional hazards model was used to test 
the significance of prognostic factors. Statistical significance 
was considered to be established when the associated p value 
was less than 0.05.
A kappa value of conformity between c-stage and 
p-stage was also determined.16 A kappa has a maximum of 
1 (indicating perfect agreement) and a minimum −1 (indicat-
ing worse than chance agreement). A value of 0 indicates an 
agreement that is no better than chance, values above 0.4 are 
usually considered indicative of “moderate” agreement, and 
values higher than 0.6 are considered “good” agreement.
RESULTS
Patient Profiles
The clinicopathologic characteristics of the 243 patients 
with resected SCLC are summarized in Table 1. Of the 243 
patients with resected SCLC, there were 213 (87.7%) men and 
30 (12.3%) women. The mean age at the time of operation was 
68.2 ± 9.5 years. Preoperative serum proGRP levels were ele-
vated in 58 patients (23.9%) and within normal limits in 185 
(76.1%) patients. The major operative mode was lobectomy/
bilobectomy (n = 174, 71.6%), followed by segmentectomy/
wedge resection (n = 51, 21.0%). More than 60% of patients 
(n = 169, 68.6%) were diagnosed as c-stage IA or IB. As for 
the pathologic stage, 93 patients (38.3%) were recognized 
as p-stage IA, and 51 (21.0%) as p-stage IB. There were 45 
(18.5%) patients in p-stage IIIA. Complete resections (R0) 
were achieved in 214 (88.1%) patients.
Postoperative Survival
The overall postoperative survival curve is shown 
in Figure 1. The 5-year survival rate of the 243 patients 
with SCLC was 52.6%. The postoperative survival curves 
according to c-stage and p-stage are shown in Figure 2. The 
5-year survival rates by c-stage and p-stage were as fol-
lows: 64.3% in c-stage IA, 45.7% in c-stage IB, 50.5% in 
c-stage IIA, 33.3% in c-stage IIB, 30.5% in c-stage IIIA, 
0% in c-stage IV, 72.3% in p-stage IA, 61.1% in p-stage 
IB, 44.8% in p-stage IIA, 40.3% in p-stage IIB, 23.4% 
in p-stage IIIA, and 0% in p-stage IV. The differences in 
survival were significant between c-stage IA and c-stage 
IB (p = 0.0423), c-stage IA and c-stage IIB (p = 0.0367), 
c-stage IA and IIIA (p = 0.0023), p-stage IA and p-stage 
IIA (p = 0.0074), p-stage IA and p-stage IIB (p = 0.0033), 
p-stage IA and p-stage IIIA (p = 0.0000), and p-stage IB 
and p-stage IIIA (p = 0.0006).
The relationship of each factor to survival, deter-
mined by univariate analysis, is shown in Table 1. Except for 
c-stage and p-stage, there was statistical significance in gen-
der (women fared better than men did), serum ProGRP level 
(worse in elevated cases), and surgical curability (R0 patients 
fared better than R1/R2 patients did). In a Cox proportional 
hazards model to predict overall survival, the following fac-
tors persisted as significant prognostic factors: gender, age, 
c-stage, and surgical curability (Table 2).
Clinicopathological Results 
According to c-Stage
The relationship of p-stage, perioperative chemo-
therapy, and surgical curability to c-stage is shown in 
Table 3. In c-stage IA + IB, 39 of 168 cases (23.2%) were 
upstaged to p-stage, and eight of 30 cases (26.7%) in 
c-stage IIIA and two (66.7%) of three in c-stage IIIB were 
downstaged to p-stage I or II. A conformity of c-stage 
and p-stage was determined to be moderate, with a kappa 
value of 0.425.
As for surgical curability, in c-stage I (IA + IB), 158 
cases (96.3%) underwent R0 resection and only six cases 
(3.7%) underwent R1/R2 resection. In c-stage II, 32 cases 
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(94.1%) underwent R0 resection and three cases (8.8%) 
underwent R1/R2. In c-stageIIIA, R0 resections were done 
in 19 cases (65.5%). The 5 year survival rates of the patients 
who underwent R0 resection with c-stage IA, c-stage IB, 
and c-stage II (IIA+IIB) were 65.4%, 51.6%, and 44.4%, 
respectively.
TABLE 1.  Characteristics of Patients with Resected Small Cell Lung Cancer and Overall Survival
N (%) 5-Year Survival (%) Comparison p Value
Gender
  Men 213 (87.7) 49.3 0.0190
  Women 30 (12.3) 79.0
Smoking
  Nonsmoker 22 (9.1) 41.6
  Ex-smoker 74 (30.5) 50.8 Nonsmoker vs. ex-smoker 0.5740
  Smoker 124 (51.0) 56.3 Nonsmoker vs. smoker 0.2253
  Unknown 23 (9.5)
Operative mode
  Wedge resection 37 (15.2) 30.6 Wedge resection vs. lobectomy/bilobectomy 0.0019
  Segmentectomy 14 (5.8) 63.6 Segmentectomy vs. lobectomy/bilobectomy 0.7848
  Lobectomy/ 
bilobectomy
174 (71.6) 58.3
  Pneumonectomy 9 (3.7) 31.8 Pneumonectomy vs. lobectomy/bilobectomy 0.1600
  Unknown 9 (3.7)
c-stage
  IA 132 (54.3) 63.3
  IB 36 (14.3) 45.7 IB vs. IA 0.0423
  IIA 25 (10.3) 50.5 IIA vs. IA 0.2531
  IIB 10 (4.1) 33.3 IIB vs. IA 0.0367
  IIIA 30 (12.3) 30.5 IIIA vs. IA 0.0023
  IIIB 3 (1.2) — — —
  IV 7 (2.9) 0 IV vs. IA 0.0000
p-stage
  IA 93 (38.3) 72.3
  IB 51 (21.0) 61.1 IB vs. IA 0.1855
  IIA 27 (11.1) 44.8 IIA vs. IA 0.0074
  IIB 17 (7.0) 40.3 IIB vs. IA 0.0033
  IIIA 45 (18.5) 23.4 IIIA vs. IA 0.0000
  IIIB 1 (0.4) — — —
  IV 9 (3.7) 0 IV vs. IA 0.0000
Preoperative treatment
  Done 27 (11.1)
  None 215 (88.5)
  Unknown 1 (0.4)
Adjuvant chemotherapy
  Done 158 (65.0) 52.0 0.5535
  None 69 (28.4) 51.8
  Unknown 16 (6.6)
Tumor marker
  CEA higher level 70 (28.8) 49.1 0.5631
  CEA normal level 173 (71.2) 53.9
  ProGRP higher level 58 (23.9) 36.0 0.0482
  ProGRP normal level 185 (76.1) 57.2
Residual tumor
  R0 214 (88.1) 57.0 0.0000
  R1/R2 23 (9.5) 10.2
  Unknown 6 (2.5)
1143Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014 Surgery for Small Cell Lung Cancer
DISCUSSION
This study, which included 243 patients who under-
went surgery in 2004, is the largest in number of patients with 
SCLC who underwent surgical intervention within just 1 year. 
It was expected that there would be low variations in preopera-
tive staging evaluation, surgical technique, and postoperative 
care for each case. For such occasions, the results of this study 
were meaningful.
The current standard treatment for patients with SCLC 
is chemotherapy and radiotherapy, except for a portion of 
early-stage patients. The MRC study3 in 1973 was a random-
ized trial, comparing surgery versus radiation alone. In that 
study, the median survival rate in the surgery group was 6.5 
months, compared with 10 months in the radiation group (p = 
0.04). After that article was published, the standard care was 
changed from surgical resection to radiotherapy. However, 
only 34 of the 71 patients (48%) who were enrolled in the sur-
gery arm actually underwent surgical resection. Most of the 
patients in the MRC study had relatively advanced disease.
Recently, several authors have reported positive results 
for surgery in patients with early-stage SCLC.17,18 Shah and 
colleagues19 reported on surgical resection for SCLC patients 
without adjuvant chemotherapy in 1992. Of 28 patients who 
underwent surgical resection, 14 had stage I disease, five had 
stage II disease, and nine had stage III disease. The actual 
5-year survival rate for patients in stage I was 57.1%, whereas 
no patients with stage II disease survived 5 years. In half of 
the patients in Shah’s study, the tumor was in a central posi-
tion. Lim and colleagues11 reported excellent survival rates for 
patients in stages I to III who underwent lung resection with 
nodal dissection for SCLC. A total of 59 patients in their study 
underwent complete R0 resection for SCLC between 1980 
and 2006, and the overall 5-year survival rate was 52%. That 
study supports the need to reevaluate surgery as the primary 
treatment and the use of clinical Tumor, Node, Metastasis 
criteria in the selection of patients with very limited SCLC 
for surgery. Weksler and colleagues20 analyzed patients in the 
Surveillance Epidemiology and End Results database, mak-
ing a retrospective analysis of a large national database. That 
study examined 3566 patients with stage I or II SCLC who 
underwent surgery from 1988 to 2007. Patients with stage 
II SCLC who had a lung resection had a median survival 
time of 25.0 months, compared with 14.0 months in patients 
with stage II SCLC who did not undergo lung resection 
(p < 0.0001). Weksler’s study concluded that surgical resec-
tion as a component of treatment for stage I or stage II SCLC 
is associated with significantly improved survival and should 
be considered in the management of early-stage SCLC.
The overall 5-year survival rate of the patients in our 
study was 52.6%. Multivariate analysis found that good prog-
nostic factors for survival were younger age, female gender, 
early-stage disease, and achieved curative resection. The same 
trends have been previously reported.11,20 Even though c-stage 
was one of the most important prognostic factors, the sur-
vival rate of the selected patients with c-stage II was favorable 
results. In particular, patients who underwent complete resec-
tion had good survival rates, not only with c-stage I, but also 
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I and II, 190 patients (95.5%) underwent R0 resection, and 
only nine underwent R1/R2 resection. Surgery was recom-
mended for the c-stage I SCLC patients; however, based on 
these results, surgical resection might also be considered for 
patients with stage II SCLC.
On the other hand, in several patients in this study, 
c-stage did not correspond well with p-stage. Among the 
patients with stage I SCLC according to preoperative evalua-
tions, 23.2% of the cases were upstaged to stage II or stage III 
postoperatively. A kappa value demonstrated moderate con-
formity between c-stage and p-stage in all cases. Vallieres and 
colleagues10 reported the same trend when comparing clini-
cal and pathological staging of SCLC, using the International 
Association for the Study of Lung Cancer database. The 
overall concordance between clinical and pathologic TNM 
staging was 58%. When grouping clinical stages I and II 
together, 19.7% were upstaged to stage pIIIA or above after 
resection according to the International Association for the 
Study of Lung Cancer database. Although there is no data 
on preoperative staging modality in the current study, inten-
sive staging before considering surgical therapy is important, 
using such tools as positron emission tomography-computed 
tomography (PET-CT),21 endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA),22 and surgi-
cal mediastinoscopy.23
Large cell neuroendocrine carcinoma (LCNEC) of the 
lung is defined as a high-grade neuroendocrine tumor no less 
than SCLC in the 1999 World Health Organization classifi-
cation of lung tumors.24 Takei et al.25 reported that 44% (24 
of 55) of operated patients who were originally diagnosed 
with SCLC (before 1999) were reclassified as LCNEC after 
the pathologic review. Studies on treatment of patients with 
SCLC naturally included many cases of LCNEC before 
LCNEC had been recognized. Thus, it is necessary to be 
aware when comparing studies performed before and after 
LCNEC was defined. The subjects of the current study are 
patients who were operated on in 2004, when LCNEC was 
well recognized.
In the present study, the survival benefit of postopera-
tive adjuvant chemotherapy was not proved. It is assumed that 
because of biases in treatment acceptance, the patients’ back-
grounds were varied, although an analysis was conducted only 
in p-stage I patients.
Limitations of this analysis include that it is a retrospec-
tive study; there is no randomization for adjuvant treatment; 
there is a lack of preoperative histopathological diagnosis 
data; there is a lack of information regarding preoperative 
staging methods; and there is no information regarding the 
aim of the preoperative treatment and whether the induction 
treatment was followed by surgery or salvage surgery.
CONCLUSION
Surgical resection for selected patients with early-stage 
SCLC, especially stage I, had good survival outcomes. Based 
on this result, surgery might also be considered in c-stage II 
SCLC. Further, a clinical trial on the surgery for patients with 




Hazard Ratio 95% CI p Value
Age, per year increase 1.038 1.015–1.062 0.001
Gender
  Men 1.00
  Women 0.356 0.142–0.893 0.028
c-stage 0.029
  IA 1.00
  IB 1.421 0.811–2.493 0.220
  IIA 1.298 0.618–2.727 0.491
  IIB 2.389 0.986–5.788 0.054
  IIIA 1.514 0.797–2.876 0.205
  IIIB 3.739 0.863–16.204 0.078
  IV 4.557 1.769–11.741 0.002
Tumor marker
  ProGRP normal level 1.00
  ProGRP higher level 1.232 0.774–1.961 0.378
Residual tumor
  R0 1.00






IA IB IIA IIB IIIA IIIB IV R0 R1/2
c-stage IA 80 23 10 8 11 0 0 126 3
IB 4 21 3 1 6 0 1 32 3
IIA 5 2 11 2 4 1 0 21 3
IIB 0 2 1 4 2 0 1 10 0
IIIA 4 2 0 2 21 0 1 19 10
IIIB 0 1 1 0 0 0 1 3 0
IV 0 0 1 0 1 0 5 3 4
R0, no residual tumor; R1/R2, microscopic or macroscopic residual tumor.
aSix patients data of curability were missing.
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